INBS — Intelligent Bio Solutions Inc.

Summary of INBS Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities totaled approximately $5.74 million, down from $8.24 million as of June 30, 2022. This decrease was attributed to expenditures related to the pilot manufacturing facility and general overhead costs.
• Net Loss: The company reported a preliminary net loss of $1.21 million ($0.08 per share) for the year ended September 30, 2022, an improvement from a net loss of $1.43 million ($0.10 per share) for the same period in the previous year. The reduction in loss was partly due to government support income of $0.31 million.
• Cash Runway: The company believes its current financial resources will cover expenses into the first half of 2023, excluding potential revenues from new markets or licensing agreements.

2. Strategic Updates and Business Highlights

• Acquisition of Intelligent Fingerprinting Limited (IFP): The acquisition is seen as a foundational move for the company, enhancing its technology platform for on-site diagnostic testing. IFP specializes in non-invasive fingerprint sweat testing for drugs of abuse.
• Product Development: The company is advancing its saliva-based glucose biosensor and has initiated clinical studies to optimize testing methods. A state-of-the-art manufacturing facility is under construction in Australia, aimed at supporting clinical development and commercial demand.
• Market Expansion: The company plans to expand IFP's product line into the U.S. market, which represents a significant opportunity, targeting a two-year timeline for FDA approval.

3. Forward Guidance and Outlook

• Sales Expectations: The company aims to start sales in Australia in Q1 2023, leveraging its existing success in the U.K. market.
• U.S. Market Strategy: The company is focused on obtaining FDA approval within two years, requiring an estimated $2 million to $3 million in funding.
• Product Pipeline: Future testing applications for the fingerprint technology are being explored, including diagnostics for various conditions and food safety testing.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The company is experiencing a cash burn due to ongoing expenditures related to the manufacturing facility and operational costs, which may impact its financial stability if revenues do not materialize as planned.
• Regulatory Risks: The timeline for FDA approval and market entry in the U.S. is uncertain and dependent on successful navigation of regulatory requirements.
• Market Competition: The company faces competition in the drug testing market, which could impact its ability to gain market share against established players.

5. Notable Q&A Insights

• Market Entry in Australia: The company is optimistic about replicating its U.K. success in Australia, with plans to introduce demo units and establish a client base quickly.
• U.K. Police Project: There is significant interest from U.K. police forces for drug testing solutions, which could lead to substantial revenue opportunities.
• Cortisol Testing: The company is assessing the market potential for cortisol testing but has not yet established a clear demand or market size.
• Grant Funding: The timing of cash flows from government grants is milestone-dependent, with expectations for reimbursement as project milestones are achieved.

Overall, Intelligent Bio Solutions is positioning itself for growth through strategic acquisitions and product development, but it faces challenges related to cash flow and regulatory approvals that could impact its short-term performance.